Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 378  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
    Article in PDF (553 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed166    
    Printed2    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
COMMENTARY
Year : 2021  |  Volume : 69  |  Issue : 5  |  Page : 1500

Commentary on Gamma Knife Surgery Combined with Octreotide Treatment of Acromegaly Patients: A Clinical Curative Effect Analysis


Department of Neurosurgery, Mayo Clinic Health System, Mankato, Minnesota, USA

Date of Web Publication30-Oct-2021

Correspondence Address:
Manish Singh Sharma
1025, Marsh Street, Mankato, Minnesota - 56001
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.329532

Rights and Permissions



How to cite this article:
Sharma MS. Commentary on Gamma Knife Surgery Combined with Octreotide Treatment of Acromegaly Patients: A Clinical Curative Effect Analysis. Neurol India 2021;69:1500

How to cite this URL:
Sharma MS. Commentary on Gamma Knife Surgery Combined with Octreotide Treatment of Acromegaly Patients: A Clinical Curative Effect Analysis. Neurol India [serial online] 2021 [cited 2021 Dec 3];69:1500. Available from: https://www.neurologyindia.com/text.asp?2021/69/5/1500/329532




Liu et al., report on 38 patients with acromegaly, who either did not opt for, or else were not suitable for surgical resection.[1] All of these patients received primary Gamma knife radiosurgery (GKS). 16 of these patients in addition received Octreotide (15 short and a single long acting formulation) for a range of 2-6 months. The decision to start Octreotide was determined by physician preference and this was not influenced by the Gamma Knife team. The rate of biochemical remission was 13.6% in the GKS group and increased to 62.5% in the group that received Octreotide in addition.

There are several factors that affect the interpretation of these results. This is a retrospective study with unestablished protocols. The average tumor size was 821.7 mm.[2] The reasons for not performing surgery, which remains the mainstay of therapy, are not elaborated. Current guidelines do not support the use of primary GKS for patients with acromegaly unless medical therapy is unavailable, unsuccessful, or not tolerated.[2] Yet 16 patients did receive Octreotide. IGF-1 levels were not available for all patients. Two patients did undergo surgery eventually for uncontrolled biochemical levels, which raises the question once again about why surgery was not the initial modality of treatment. Average follow up was limited at 2.9 + 1.3 years. Post treatment radiographic follow up was not available.

Given these limitations, what does appear to be clear is that GKS may be the least effective modality of initial treatment for patients with acromegaly.



 
  References Top

1.
Liu HB, Wang W. Gamma Knife Surgery Combined with Octreotide Treatment of Acromegaly Patients: A Clinical Curative Effect analysis. Neurol India [Epub ahead of print].  Back to cited text no. 1
    
2.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Endocrine Society. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3933-51.  Back to cited text no. 2
    




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow